

building a global oncology company

Founded in 2000, Novocure develops and commercializes an innovative therapy for solid tumors: Tumor Treating Fields (TTFields). After more than 20 years, Novocure continues to grow, fueled by a collective drive for innovation.



our growth, at a glance

26,000+

PATIENTS TREATED TO DATE

1,300+

EMPLOYEES WORLDWIDE

4

INDICATIONS IN LATE-STAGE PIPELINE

3

FDA APPROVED INDICATIONS


Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of our innovative therapy, TTFIELDS. **TTFIELDS** are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms, including disruption of mitosis, enhancement of anti-tumor immunity, interference with cell movement and migration and downregulation of DNA damage response.

In 2000, our founder, Professor Yoram Palti, sought to leverage his expertise in biophysics to develop a new way to treat cancer that would destroy tumor cells while sparing healthy tissue and avoiding many of the life-altering side effects of existing cancer therapies.

"Nobody understood what I was doing," Professor Palti said of his early development of Tumor Treating Fields.

Palti's initial research from his basement laboratory evolved to become Novocure – an international oncology company with more than 1,300 employees and operations in North America, Europe, the Middle East and Asia.

Today, our commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. We have ongoing or completed clinical studies investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.




Professor Yoram Palti, Founder

our mission

Together with our patients, we strive to extend survival in some of the most aggressive forms of cancer through the development and commercialization of our innovative therapy, Tumor Treating Fields.

our values

INNOVATION **FOCUS** **DRIVE**
COURAGE **TRUST** **EMPATHY**



TTFIELDS THERAPY IS A PLATFORM THERAPY, WITH SIGNIFICANT POTENTIAL FOR VERSATILITY ACROSS SOLID TUMOR TYPES AND LINES OF THERAPY.

“We are diligently working to reach additional patients in our current markets, expand into new markets, enhance our products and treat patients in new indications.”

– William Doyle, Novocure’s Executive Chairman



Our portable Tumor Treating Fields therapy is designed to be delivered continuously to allow patients to go about their daily activities while receiving treatment.




Tumor Treating Fields are generated via pairs of transducer arrays placed directly on the skin’s surface in the region surrounding the tumor.



our pipeline

With several late-stage trials nearing completion, we are approaching a critical inflection point for cancer patients and our company.



our global footprint

Headquartered in Root, Switzerland and with a growing global footprint, Novocure has regional operating centers in Portsmouth, New Hampshire and Tokyo, as well as a research center in Haifa, Israel. Our active markets are below.



“We are committed to making our therapy available to all the patients who may benefit. We have a unique opportunity to make an even larger impact as we bring our therapy to more patients throughout the world.”

– Asaf Danziger, CEO

